Total Funding
83
62
Total FundingPost-IPO Equity raised
Growth Score
-8 pts
Heat Score
-30 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
46592
Longeveron is a biotechnology company that focuses on developing cellular therapies for chronic aging-related and life-threatening diseases.
- Joshua Hare: Co-Founder and chief science officer
- Donald Soffer: Co-Founder
About the Company
Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases. Longeveron's primary investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of healthy adult donors. Lomecel-B™ exhibits various potential mechanisms of action,
including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects. These properties make it applicable across a range of diseases. Longeveron is currently conducting clinical trials for Lomecel-B™ in three areas: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.
